<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Simulations Plus Inc — News on 6ix</title>
<link>https://6ix.com/company/simulations-plus-inc</link>
<description>Latest news and press releases for Simulations Plus Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 11:55:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/simulations-plus-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c02e78dffbe2df118617.webp</url>
<title>Simulations Plus Inc</title>
<link>https://6ix.com/company/simulations-plus-inc</link>
</image>
<item>
<title>Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-collaboration-with-lonza-and-us-fda-to-advance-predictive-frameworks-for-complex-oral-drug-products</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-collaboration-with-lonza-and-us-fda-to-advance-predictive-frameworks-for-complex-oral-drug-products</guid>
<pubDate>Tue, 21 Apr 2026 11:55:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., April 21, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG ("Lonza"), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a mech</description>
</item>
<item>
<title>Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-expands-global-access-to-model-informed-drug-development-training-through-its-2026-spring-school</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-expands-global-access-to-model-informed-drug-development-training-through-its-2026-spring-school</guid>
<pubDate>Mon, 20 Apr 2026 11:55:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., April 20, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry’s future workforce.</description>
</item>
<item>
<title>Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-reports-second-quarter-fiscal-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-reports-second-quarter-fiscal-2026-financial-results</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Revenue grew 8% with increases in both software and services RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP)</description>
</item>
<item>
<title>Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-second-quarter-fiscal-year-2026-earnings-and-conference-call-date</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-second-quarter-fiscal-year-2026-earnings-and-conference-call-date</guid>
<pubDate>Thu, 26 Mar 2026 20:05:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., March 26, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report second quarter fiscal 2026 financial results after the market close on Thursday, April 9, 2026.</description>
</item>
<item>
<title>Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-strategic-collaboration-programs-for-ai-enabled-modeling</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-strategic-collaboration-programs-for-ai-enabled-modeling</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Co-development initiatives to advance next-generation workflows, accelerate adoption, and expand the role of AI within model-informed drug development</description>
</item>
<item>
<title>Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-convenes-industry-and-regulatory-leaders-to-define-responsible-ai-in-midd</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-convenes-industry-and-regulatory-leaders-to-define-responsible-ai-in-midd</guid>
<pubDate>Tue, 03 Mar 2026 12:55:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., March 03, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a high-impact panel discussion, "From Debate to Deployment: Responsible, Practical AI in MIDD," to be held during the upcoming American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting on March 5, 2026 at 12:00 PM MST in Denver, CO.</description>
</item>
<item>
<title>Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-extensions-u-234500536</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-extensions-u-234500536</guid>
<pubDate>Mon, 09 Feb 2026 23:45:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., February 09, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the extension of two separate research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). The extended projects support ongoing federal research efforts focused on the dev</description>
</item>
<item>
<title>Simulations Plus to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-participate-upcoming-investor-210500019</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-participate-upcoming-investor-210500019</guid>
<pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., February 03, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the upcoming investor conferences:</description>
</item>
<item>
<title>Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-highlights-platform-innovation-210500516</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-highlights-platform-innovation-210500516</guid>
<pubDate>Wed, 21 Jan 2026 21:05:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., January 21, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today hosted its 2026 Virtual Investor Day, outlining how the Company is advancing an integrated, AI-enabled platform to support the evolving needs of the drug development industry and its regulators.</description>
</item>
<item>
<title>Simulations Plus Reports First Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-reports-first-quarter-210500761</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-reports-first-quarter-210500761</guid>
<pubDate>Thu, 08 Jan 2026 21:05:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., January 08, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025.</description>
</item>
<item>
<title>Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-host-virtual-investor-125000568</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-host-virtual-investor-125000568</guid>
<pubDate>Thu, 18 Dec 2025 12:50:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., December 18, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will host a virtual Investor Day on Wednesday, January 21, 2026.</description>
</item>
<item>
<title>Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-first-quarter-125000820</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-first-quarter-125000820</guid>
<pubDate>Wed, 17 Dec 2025 12:50:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., December 17, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026.</description>
</item>
<item>
<title>Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-positioned-capitalize-fda-125500199</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-positioned-capitalize-fda-125500199</guid>
<pubDate>Tue, 09 Dec 2025 12:55:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., December 09, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokineti</description>
</item>
<item>
<title>Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-reports-fourth-quarter-210500239</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-reports-fourth-quarter-210500239</guid>
<pubDate>Mon, 01 Dec 2025 21:05:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., December 01, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025.</description>
</item>
<item>
<title>Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-preliminary-fiscal-115000524</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-preliminary-fiscal-115000524</guid>
<pubDate>Wed, 22 Oct 2025 11:50:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., October 22, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and management outlook for fiscal year 2026 as follows:</description>
</item>
<item>
<title>Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-institute-medical-biology-115000460</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-institute-medical-biology-115000460</guid>
<pubDate>Tue, 29 Jul 2025 11:50:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., July 29, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) have been published in the America</description>
</item>
<item>
<title>Simulations Plus Invests in Clinical Development Technology Company Nurocor</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-invests-clinical-development-201500319</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-invests-clinical-development-201500319</guid>
<pubDate>Mon, 14 Jul 2025 20:15:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., July 14, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor.</description>
</item>
<item>
<title>Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-reports-third-quarter-200500005</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-reports-third-quarter-200500005</guid>
<pubDate>Mon, 14 Jul 2025 20:05:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., July 14, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025.</description>
</item>
<item>
<title>Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-rescheduling-third-200500921</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-announces-rescheduling-third-200500921</guid>
<pubDate>Wed, 18 Jun 2025 20:05:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., June 18, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has rescheduled the release of its financial results and conference call for the third fiscal quarter ended May 31, 2025, which had previously been scheduled for July 2, 2025.</description>
</item>
<item>
<title>Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum</title>
<link>https://6ix.com/company/simulations-plus-inc/news/simulations-plus-participate-citizens-medical-115000185</link>
<guid isPermaLink="true">https://6ix.com/company/simulations-plus-inc/news/simulations-plus-participate-citizens-medical-115000185</guid>
<pubDate>Thu, 12 Jun 2025 11:50:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., June 12, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices and Healthcare Services Forum taking place in Boston, Massachusetts. Mr. O’Connor will host one-on-one mee</description>
</item>
</channel>
</rss>